反应 #1726709

ord-764a21ddb1184ccebf879e23a3e47f8b

反应方程式

O=C1CCNCC1
4-piperidone
CC(=O)Nc1ccc(O)c(C(N)=O)c1
5-acetamido-2-hydroxybenzamide
C1COCCN1
morpholine
O=C1NC2(CCNCC2)Oc2ccccc21
Compound 9
O=C1NC2(CCNCC2)Oc2ccccc21
spiro[2H-1,3-benzoxazin-2,4′-piperidin]-4-(3H)-one

反应条件

详细条件
See reaction.notes.procedure_details.

后处理

  1. 1
    温度is refluxed for 48 hr
  2. 2
    洗涤washed with water, brine
  3. 3
    干燥dried over Na2SO4
  4. 4
    其他After solvent removal by rotoevaporation
  5. 5
    其他the crude product is purified by preparative TLC

实验过程

A mixture of 24 mg (0.077 mmol) of N-[4,8-dimethoxyquinoline-2-yl)carbonyl]-4-piperidone, 15 mg (0.077 mmol) of 5-acetamido-2-hydroxybenzamide, and 0.020 mL of morpholine in 3 mL of methanol is refluxed for 48 hr. The reaction mixture is diluted with ethyl acetate, and washed with water, brine, and dried over Na2SO4. After solvent removal by rotoevaporation, the crude product is purified by preparative TLC to give 11 mg (0.022 mmol, 30% yield) of 6-acetamido-1′-[4,8-dimethoxyquinoline-2-yl)carbonyl]spiro[2H-1,3-benzoxazin-2,4′-piperidin]-4-(3H)-one (Compound 9): 1H NMR (DMSO-d6): δ 2.02 (s, 3H), 3.95 (s, 3H), 4.06 (s, 3H), 7.03 (d, 1H), 8.19 (s, 1H), 7.24 (d of d, 1H), 7.52 (d of d, 1H), 7.67 (m, 2H), 8.02 (d, 1H), 8.82, (s, 1H) and 9.98 ppm (s, 1H). MS m/z: 491.1 (M+H)+, 513.2 (M+Na)+.

来源

DOI: 10.6084/m9.figshare.5104873.v1专利: US08110570B2uspto-grants-2012_02